The Agency may temporarily authorise the use of medicinal products referred to in Article 9 paragraph 2 letter d on certain persons or on certain categories of persons outside clinical trials.
It may also authorise the temporary or quantitative marketing of a medicinal product to bridge the temporary unavailability of an identical medicinal product authorised in Switzerland, provided that:
the medicinal product is authorised in another country that has equivalent medicinal product control; and
no essentially identical medicinal product is authorised and available in Switzerland.
0 commentaries
No commentaries are available for this article yet.